Stockscreener 앱 받기
38.63
0.21%
-0.08
시장 영업 전:
38.65
0.02
+0.05%
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - MSN
How to manage a losing position in Exelixis Inc.2025 Top Gainers & Stepwise Trade Signal Implementation - Newser
Developing predictive dashboards with Exelixis Inc. dataWeekly Volume Report & High Conviction Buy Zone Picks - Newser
Will Exelixis Inc. stock go up soonQuarterly Performance Summary & Daily Volume Surge Signals - Newser
Exelixis Inc. Flashes Rebound Signal in Oversold ConditionJuly 2025 Outlook & High Accuracy Investment Entry Signals - beatles.ru
Sector ETF performance correlation with Exelixis Inc.July 2025 Highlights & Daily Stock Trend Watchlist - Newser
When is the best time to exit Exelixis Inc.2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Should you wait for a breakout in Exelixis Inc.Market Trend Report & Safe Capital Growth Tips - Newser
What candlestick patterns are forming on Exelixis Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Price momentum metrics for Exelixis Inc. explainedQuarterly Growth Report & Daily Entry Point Alerts - Newser
Will EXEL's Share Repurchase Program Boost Value for Investors? - sg.finance.yahoo.com
Can Exelixis Inc. Rally Enough to Break EvenJuly 2025 Opening Moves & Growth Focused Stock Reports - classian.co.kr
Is Exelixis Inc. stock forming a cup and handleBear Alert & Fast Gain Stock Trading Tips - thegnnews.com
Is Exelixis Inc. building a consolidation base2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - MSN
Live Scanner Shows Breakout on Exelixis Inc.Portfolio Return Summary & Weekly Breakout Opportunity Watchlist - newsimpact.co.kr
Exelixis reports Q2 rev. below consensus, net product revenues 2% lower YoY. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - FinancialContent
H.C. Wainwright Maintains Buy on Exelixis (EXEL) Despite STELLAR-305 Phase 3 Setback - MSN
Signal strength of Exelixis Inc. stock in tech scannersInflation Watch & Community Shared Stock Ideas - Newser
H.C. Wainwright Maintains Buy Rating on Exelixis Despite STELLAR-305 Phase 3 Setback - AInvest
What makes Exelixis Inc. stock price move sharplyStop Loss & Free Community Supported Trade Ideas - thegnnews.com
Did You Suffer Losses in Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Exelixis Q2 net product revs down 2% at $531.3mln, below consensus. - AInvest
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - MarketScreener
Momentum Screeners Rank Exelixis Inc. in Top 5 TodayQuarterly Market Review & Scalable Portfolio Growth Ideas - newsimpact.co.kr
Will Exelixis Inc. continue its uptrendJuly 2025 Action & Expert Curated Trade Setups - Newser
Is it too late to sell Exelixis Inc.Quarterly Growth Report & AI Forecast for Swing Trade Picks - Newser
EXEL Investor Notice: Levi & Korsinsky Investigates Exelixis, Inc. for Securities Law Violations - ACCESS Newswire
Pan-Tumor Rollover Study: Bristol-Myers Squibb, Exelixis, and Novartis Collaborate on Long-Term Cancer Treatment - AInvest
Investigation Underway: Exelixis, Inc. (EXEL)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire
Exelixis Q2 2025 presentation slides: Cabozantinib franchise grows 19% YoY By Investing.com - Investing.com Canada
Statistical indicators supporting Exelixis Inc.’s strengthJuly 2025 Retail & Fast Entry High Yield Tips - Newser
Exelixis Inc. Builds Base for Possible ReboundJuly 2025 Highlights & Safe Capital Growth Plans - sundaytimes.kr
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Investors in Exelixis, Inc. (EXEL) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Ongoing Securities Investigation into Exelixis, Inc. (EXEL)Contact Levi & Korsinsky - ACCESS Newswire
Exelixis Gains 15.6% YTD: How Should You Play the Stock? - The Globe and Mail
Exelixis Inc. Rebounds From Oversold Zone — Now What2025 Stock Rankings & AI Forecast for Swing Trade Picks - mustnews.co.kr
Lost Money on Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth? - Yahoo Finance
PNC Financial Services Group Inc. Acquires 1,029 Shares of Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis (EXEL) Price Target Lowered by HC Wainwright, Analysts Maintain Overall Positive Outlook - AInvest
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What Fibonacci levels say about Exelixis Inc. reboundWeekly Stock Movement Prediction Watchlist - Newser
Exelixis stock price target lowered to $46 at H.C. Wainwright on SCCHN trial halt - Investing.com Nigeria
0.94%
1.72%
자본화:
|
볼륨(24시간):